Sandler Capital Management’s AstraZeneca AZN Stock Holding History

Sandler Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,500	Closed	-$210K	–	147
2025 Q2	$210K	Sell	1,500 -500	-25%	-$70.1K	0.06%	142
2025 Q1	$294K	Hold	2,000	–	–	0.07%	111
2024 Q4	$262K	Hold	2,000	–	–	0.03%	148
2024 Q3	$312K	Hold	2,000	–	–	0.04%	136
2024 Q2	$312K	Hold	2,000	–	–	0.03%	116
2024 Q1	$271K	Hold	2,000	–	–	0.02%	132
2023 Q4	$269K	Hold	2,000	–	–	0.02%	101
2023 Q3	$271K	Hold	2,000	–	–	0.03%	102
2023 Q2	$286K	Hold	2,000	–	–	0.02%	85
2023 Q1	$278K	Hold	2,000	–	–	0.03%	87
2022 Q4	$271K	Hold	2,000	–	–	0.03%	81
2022 Q3	$219K	Buy	+2,000	New	+$254K	0.03%	77
2014 Q3	–	Sell	-266,000	Closed	-$19.8M	–	184
2014 Q2	$19.8M	Buy	+266,000	New	+$19.2M	0.83%	34

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sandler Capital Management's AZN Position: Q3 2025 in Review

Sandler Capital Management sold out of AstraZeneca (AZN) in Q3 2025, closing a stake of 1,500 shares — an estimated $210K sold.

Sandler Capital Management first reported a position in AZN in Q2 2014 and held it in 13 quarters. The position peaked at $19.8M in Q2 2014. 1,289 funds tracked by Wall St. Rank hold AZN as of Q3 2025.

Sandler Capital Management reported no remaining AstraZeneca position as of Q3 2025 after selling out during the quarter.
Sandler Capital Management sold 1,500 AstraZeneca shares in Q3 2025, an estimated $210K.
Sandler Capital Management first reported a position in AstraZeneca in Q2 2014 and held it in 13 quarters.
Sandler Capital Management's AstraZeneca position peaked at $19.8M in Q2 2014.
1,289 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.

Based on Sandler Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.